View article

Acute lung injury (ALI) and its most severe form, the acute respiratory distress syndrome (ARDS) are frequent complications in critically ill patients and are responsible for significant morbidity and mortality (1, 2). Treatment of the underlying disease and excellent supportive care using “lung-protective” strategies of mechanical ventilation (3) contribute to successful clinical outcomes. However, aside from the use of activated protein C in the subset of ALI/ARDS patients with sepsis (4), specific therapies are lacking, and the cascade of events leading to ALI and ARDS, once initiated, is much less amenable to specific treatment modalities.

Regardless of the underlying illness, the clinical and pathologic manifestations of ALI/ARDS are very similar, indicating the existence of final common pathways that represent potential therapeutic targets (1, 5). In essence, these syndromes reflect severe injury leading to dysfunction and …